A bit of interesting news has been flying under the radar involving a legal skirmish between Japanese drug maker Daiichi-Sankyo, manufacturer of the hypertension medication Benicar, and a couple of upstart companies that would like to produce and market their own generic versions. A federal judge's recent ruling on non-infringement of patent will allow Apotex, Inc. to enter the generic market earlier than it would have otherwise – but given the ongoing controversies over the drug, it's hard to know why it would want to.